{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:32:32Z","timestamp":1793971952816,"version":"4.8.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.esmoop.2023.101627","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T01:03:36Z","timestamp":1694480616000},"page":"101627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Genomic characterization of thymic epithelial tumors in a real-world dataset"],"prefix":"10.1016","volume":"8","author":[{"given":"K.","family":"Kurokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shukuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Greenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2023.101627_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101627_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2013.0072","article-title":"Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology","volume":"11","author":"Ettinger","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"15","key":"10.1016\/j.esmoop.2023.101627_bib3","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101627_bib4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A\u00a0multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101627_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000421-199308000-00014","article-title":"EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma","volume":"16","author":"Bonomi","year":"1993","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101627_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101627_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101627_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101627_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2023.101627_bib10","article-title":"Frequent genetic alterations and their clinical significance in patients with thymic epithelial tumors","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101627_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.esmoop.2023.101627_bib12","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.esmoop.2023.101627_bib13","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2023.101627_bib14","doi-asserted-by":"crossref","unstructured":"Schenker M, Burotto M, Richardet M, Ciuleanu T, Goncalves A, Steeghs N. CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. The AACR Annual Meeting. April 8-13, 2022; New Orleans, LA.","DOI":"10.1158\/1538-7445.AM2022-CT022"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101627_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101627_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne(R)CDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2023.101627_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101627_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101627_bib19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A\u00a0novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J\u00a0Mol Diagn"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101627_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol Oncol Res"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101627_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/carcin\/bgx094","article-title":"The genomic and epigenomic landscape in thymic carcinoma","volume":"38","author":"Saito","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.esmoop.2023.101627_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2016.01.004","article-title":"Medical treatment involving investigational drugs and genetic profile of thymic carcinoma","volume":"93","author":"Asao","year":"2016","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101627_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cllc.2020.11.010","article-title":"Mutation profile of thymic carcinoma and thymic neuroendocrine tumor by targeted next-generation sequencing","volume":"22","author":"Sakane","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101627_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/oncolo\/oyac115","article-title":"Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers","volume":"27","author":"Girard","year":"2022","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.esmoop.2023.101627_bib25","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/hmg\/4.10.1883","article-title":"Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers","volume":"4","author":"Suzuki","year":"1995","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101627_bib26","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/1759-7714.13765","article-title":"Mutation profile and immunoscore signature in thymic carcinomas: an exploratory study and review of the literature","volume":"12","author":"Asselta","year":"2021","journal-title":"Thorac Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101627_bib27","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s10637-011-9774-6","article-title":"Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies","volume":"30","author":"Weiss","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.esmoop.2023.101627_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.645745","article-title":"Analysis of adenoviral p53 gene therapy clinical trials in recurrent head and neck squamous cell carcinoma","volume":"11","author":"Sobol","year":"2021","journal-title":"Front Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2023.101627_bib29","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","article-title":"A\u00a0biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"36","key":"10.1016\/j.esmoop.2023.101627_bib30","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2023.101627_bib31","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101627_bib32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2014.08.020","article-title":"Genetic profiling of thymic carcinoma using targeted next-generation sequencing","volume":"86","author":"Shitara","year":"2014","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101627_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mco2.103","article-title":"Targeting DNA repair pathway in cancer: mechanisms and clinical application","volume":"2","author":"Wang","year":"2021","journal-title":"MedComm (2020)"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101627_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/CCO.0000000000000390","article-title":"Targeting EZH2 in cancer therapy","volume":"29","author":"Yamagishi","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2023.101627_bib35","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.101627_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101364","article-title":"The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles","volume":"18","author":"Sanaei","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.esmoop.2023.101627_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-rearranged leukemias-an update on science and clinical approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front Pediatr"},{"key":"10.1016\/j.esmoop.2023.101627_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.029","article-title":"Targeted inhibitors and antibody immunotherapies: novel therapies for paediatric leukaemia and lymphoma","volume":"164","author":"Brivio","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101627_bib39","article-title":"Pan-cancer landscape analysis reveals recurrent KMT2A-MAML2 gene fusion in aggressive histologic subtypes of thymoma","volume":"4","author":"Massoth","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2023.101627_bib40","doi-asserted-by":"crossref","first-page":"a019133","DOI":"10.1101\/cshperspect.a019133","article-title":"DNA methylation in mammals","volume":"6","author":"Li","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101627_bib41","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1093\/nar\/27.11.2291","article-title":"The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors","volume":"27","author":"Robertson","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.esmoop.2023.101627_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.imlet.2021.06.005","article-title":"Downregulation of DNMT3a expression by RNAi and its effect on NF-kappaBs expression of thymic epithelial cells","volume":"237","author":"Meng","year":"2021","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101627_bib43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cac2.12377","article-title":"Targeting RAS mutants in malignancies: successes, failures, and reasons for hope","volume":"43","author":"Yang","year":"2023","journal-title":"Cancer Commun (Lond)"},{"issue":"17","key":"10.1016\/j.esmoop.2023.101627_bib44","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101627_bib45","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"6349","key":"10.1016\/j.esmoop.2023.101627_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101627_bib47","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101627_bib48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101627_bib49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2023.101627_bib50","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2023.101627_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101627_bib52","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A\u00a0specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat Genet"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:54Z","timestamp":1761856194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923008621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2059702923008621"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101627","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic characterization of thymic epithelial tumors in a real-world dataset","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101627"}}